Table 3.
Drug | U-CH1 | U-CH2 | ||||||
---|---|---|---|---|---|---|---|---|
IC50 (µM, absolute) | IC50 (µM, relative) | Maximal inhibition (%) | n | IC50 (µM, absolute) | IC50 (µM, relative) | Maximal inhibition (%) | n | |
Afatinib | 0.54 | 0.38 | 93 | 6 | 9.4 | 8.8 | 98 | 7 |
Palbociclib | 11.4 | 10.8 | 96 | 6 | 20.8 | 19.5 | 94 | 6 |
RDEA119 | – | 2.4 | 59 | 2 | 24.5 | 24.4 | 94 | 4 |
AZD0530 | 2.7 | 1.5 | 85 | 5 | 29.4 | 26.6 | 100 | 3 |
AZD2014 | 0.94 | 0.35 | 72 | 7 | – | 0.61 | 53 | 8 |
AZD4054 | 11.9 | 11.0 | 84 | 2 | 18.8 | 19.2 | 100 | 2 |
Data generated includes geometric mean IC50, and arithmetic mean of maximal inhibition. Absolute IC50 is the dose that reduces resazurin fluorescence by 50%, relative to positive and negative controls. Relative IC50 is the dose that has 50% of the maximal inhibition for a given drug. Where values are absent this represents the drug never reaching 50% inhibition in several replicate experiments.